Year archive

Akeso, Inc. — 2022 filings

All 53 regulatory filings released by Akeso, Inc. (9926) in 2022, sourced directly from the official regulator.

53 Filings

2022 Period

2022 filings (53)

Filing	Released	Lang
INSIDE INFORMATION ANNOUNCEMENT - ENTERING INTO LICENSE AGREEMENT FOR UP TO US$5 BILLION FOR IVONESCIMAB (PD-1/VEGF BISPECIFIC) WITH SUMMIT THERAPEUTICS INC. Regulatory Filings	2022-12-06	English
INSIDE INFORMATION ANNOUNCEMENT - PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE Regulatory Filings	2022-12-06	English
VOLUNTARY ANNOUNCEMENT - VESTING OF RESTRICTED SHARE UNITS UNDER THE PRE-IPO RSU SCHEME Regulatory Filings	2022-12-02	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2022 Regulatory Filings	2022-12-02	English
VOLUNTARY ANNOUNCEMENT - IVONESCIMAB(PD-1/VEGF, AK112) WAS GRANTED THREE BREAKTHROUGH THERAPY DESIGNATIONS BY CENTER FOR DRUG EVALUATION(CDE) OF THE NMPA Regulatory Filings	2022-11-14	English
VOLUNTARY ANNOUNCEMENT - IVONESCIMAB (PD-1/VEGF, AK112) COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSQ-NSCLC PATIENTS WHO HAVE FAILED TO EGFR-TKI Regulatory Filings	2022-11-03	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2022 Regulatory Filings	2022-11-02	English
VOLUNTARY ANNOUNCEMENT - (CADONILIMAB INJECTION) BEING INCLUDED IN CSCO GUIDELINES FOR CERVICAL CANCER TREATMENT (2022) Regulatory Filings	2022-10-17	English
VOLUNTARY ANNOUNCEMENT - APPROVAL OF COMMENCEMENT OF PHASE IB/II CLINICAL TRIAL OF IVONESCIMAB (PD-1/VEGF, AK112) COMBINED WITH DREBUXELIMAB (CD73, AK119) FOR THE TREATMENT OF ADVANCED SOLID Regulatory Filings	2022-10-14	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2022 Regulatory Filings	2022-10-07	English
2022 INTERIM REPORT Regulatory Filings	2022-09-28	English
CONTINUING CONNECTED TRANSACTIONS WITH CHIA TAI TIANQING IN RELATION TO PHASE III REGISTRATION TRIAL OF PENPULIMAB (PD-1 MONOCLONAL ANTIBODY, AK105) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA MASTE Regulatory Filings	2022-09-20	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2022 Regulatory Filings	2022-09-06	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT Regulatory Filings	2022-08-23	English
DATE OF BOARD MEETING Regulatory Filings	2022-08-11	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2022 Regulatory Filings	2022-08-02	English
Next Day Disclosure Return Regulatory Filings	2022-07-15	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2022-07-15	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE Regulatory Filings	2022-07-08	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2022 Regulatory Filings	2022-07-06	English
INSIDE INFORMATION ANNOUNCEMENT - CADONILIMAB INJECTION OBTAINED NMPA'S MARKETING APPROVAL IN CHINA Regulatory Filings	2022-06-29	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, JUNE 28, 2022 Regulatory Filings	2022-06-28	English
Share Option Scheme Regulatory Filings	2022-06-13	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2022 Regulatory Filings	2022-06-07	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE II CLINICAL TRIAL OF IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) IN COMBINATION OF CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PUBLISHED Regulatory Filings	2022-06-06	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE IB/II CLINICAL TRIAL OF IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) MONOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER PUBLISHED AT THE 202 Regulatory Filings	2022-06-06	English
VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION OF PHASE II CLINICAL DATA OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104) FOR THE FIRST-LINE TREATMENT OF R/M CERVICAL CANCER AT 2022 ASCO Regulatory Filings	2022-06-06	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, JUNE 28, 2022 Regulatory Filings	2022-06-01	English
NOTICE OF ANNUAL GENERAL MEETING Regulatory Filings	2022-06-01	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITORS; PROPOSED ADOPTION OF THE SH Regulatory Filings	2022-06-01	English
PROPOSED ADOPTION OF THE SHARE OPTION SCHEME Regulatory Filings	2022-05-30	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2022 Regulatory Filings	2022-05-06	English
2021 ANNUAL REPORT Regulatory Filings	2022-04-28	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2022 Regulatory Filings	2022-04-07	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021 Regulatory Filings	2022-03-30	English
DATE OF BOARD MEETING Regulatory Filings	2022-03-17	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BISPECIFIC ANTIBODY, AK104) IN COMBINATION WITH DOCETAXEL OBTAINED APPROVAL TO INITIATE PHASE II CLINICAL TRIAL TO TREAT NSCLC Regulatory Filings	2022-03-07	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2022 Regulatory Filings	2022-03-02	English
VOLUNTARY ANNOUNCEMENT - AKESO IN COLLABORATION WITH CHIPSCREEN BIOSCIENCES INITIATED A CLINICAL TRIAL OF PD-1/CTLA-4 BI-SPECIFIC ANTIBODY IN COMBINATION WITH CHIAURANIB TO TREAT PD-(L) 1 PRETREA Regulatory Filings	2022-03-01	English
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL OF NGF MONOCLONAL ANTIBODY (AK115) FOR THE TREATMENT OF PAIN (INCLUDING CANCER PAIN) FIRSTLY INTRODUCED BY AKESO IN THE FIELD OF PAIN Regulatory Filings	2022-02-09	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2022 Regulatory Filings	2022-02-08	English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME Regulatory Filings	2022-01-30	English
CONTINUING CONNECTED TRANSACTIONS FURTHER INFORMATION IN RELATION TO EXCLUSIVE SALES AGREEMENT OF PENPULIMAB MONOCLONAL ANTIBODY Regulatory Filings	2022-01-30	English
VOLUNTARY ANNOUNCEMENT - LIGUFALIMAB (CD47 MONOCLONAL ANTIBODY, AK117) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) AND CHEMOTHERAPY AS FIRST-LINE THERAPY FOR UNRESECTABLE LO Regulatory Filings	2022-01-30	English
VOLUNTARY ANNOUNCEMENT - IVONESCIMAB (PD-1/VEGF BI-SPECIFIC, AK112) COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF EGFR-TKI RESISTANT EGFR MUTATION ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANC Regulatory Filings	2022-01-30	English
VOLUNTARY ANNOUNCEMENT- RESULTS OF PHASE IB/II CLINICAL TRIAL OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CHEMOTHERAPY AS FIRST-LINE THERAPY FOR ADVANCED GASTRIC CANCER&# Regulatory Filings	2022-01-20	English
VOLUNTARY ANNOUNCEMENT- RESULTS OF PHASE IB/II CLINICAL TRIAL OF CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104) COMBINED WITH CHEMOTHERAPY AS FIRST-LINE THERAPY FOR ADVANCED GASTRIC C Regulatory Filings	2022-01-17	English
VOLUNTARY ANNOUNCEMENT - LIGUFALIMAB (CD47 MONOCLONAL ANTIBODY, AK117) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO Regulatory Filings	2022-01-10	English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME Regulatory Filings	2022-01-06	English
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENT Regulatory Filings	2022-01-05	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINE Regulatory Filings	2022-01-04	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2021 Regulatory Filings	2022-01-04	English
VOLUNTARY ANNOUNCEMENT - CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY, AK104) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMEN Regulatory Filings	2022-01-03	English